Pelvic MRI as the "gold standard" in the subsequent evaluation of ultrasound-indeterminate adnexal lesions: a systematic review
- PMID: 24183731
- DOI: 10.1016/j.ygyno.2013.10.022
Pelvic MRI as the "gold standard" in the subsequent evaluation of ultrasound-indeterminate adnexal lesions: a systematic review
Abstract
Objective: Incidentally discovered adnexal masses are common, posing a challenging diagnostic problem because imaging features of benign and malignant overlap. Thus, once an adnexal lesion has been detected, the primary goal of further imaging is accurate tissue characterization resulting in surgery only for lesions that are indeterminate or frankly malignant. This study aims to conduct a systematic review, following the PRISMA guidelines, and critically appraise pelvic MR Imaging as the preferred advanced second imaging test, as regards detection of ovarian cancer and assessment of indeterminate adnexal masses, with respect to pre-operatively improving the assignment of these patients to the appropriate level of care.
Methods: A comprehensive computerized systematic literature search of English language studies was performed (from 2002 to 2012) of PubMed, EMBASE, Scopus, Evidence Based Medicine Reviews (Cochrane Database and Cochrane Central Register of Controlled Trials), and Google Scholar. Relevant article reference lists were hand searched.
Results: Computerized database search revealed 37 citations of relevance, 10 of which fulfilled the inclusion/exclusion criteria. From the aforementioned, 8 articles were acquired (2 authors were contacted but did not respond) as well as assessed with AHRQ, QUADAS, and STARD evaluation tools. Finally, 6 papers (5 prospective and 1 retrospective) were included in the systematic review.
Conclusions: MRI with intravenous (IV) contrast administration provides the highest post-test probability of ovarian cancer detection. However, the preponderant contribution of MRI in adnexal mass evaluation is its specificity because it provides confident diagnosis of many benign adnexal lesions.
Keywords: Adnexal lesions; Ovarian cancer; Pelvic MRI; Second test; Ultrasound-indeterminate.
© 2013.
Similar articles
-
Guideline No. 403: Initial Investigation and Management of Adnexal Masses.J Obstet Gynaecol Can. 2020 Aug;42(8):1021-1029.e3. doi: 10.1016/j.jogc.2019.08.044. J Obstet Gynaecol Can. 2020. PMID: 32736853 Review.
-
[MR imaging of the pelvis in characterization of adnexal masses].Zentralbl Gynakol. 2005 Dec;127(6):373-9. doi: 10.1055/s-2005-836917. Zentralbl Gynakol. 2005. PMID: 16341980 Review. German.
-
Gadolinium-DOTA enhanced MR imaging of adnexal tumors.J Comput Assist Tomogr. 1990 Nov-Dec;14(6):939-49. doi: 10.1097/00004728-199011000-00014. J Comput Assist Tomogr. 1990. PMID: 2229572
-
MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization.AJR Am J Roentgenol. 2010 Feb;194(2):311-21. doi: 10.2214/AJR.09.3522. AJR Am J Roentgenol. 2010. PMID: 20093590 Review.
-
Adnexal masses in the premenopausal patient.Clin Obstet Gynecol. 2015 Mar;58(1):47-52. doi: 10.1097/GRF.0000000000000087. Clin Obstet Gynecol. 2015. PMID: 25608252 Review.
Cited by
-
A quantitative MRI-based approach to estimate the permeation and retention of nanomedicines in tumors.J Control Release. 2024 Apr;368:728-739. doi: 10.1016/j.jconrel.2024.03.019. Epub 2024 Mar 19. J Control Release. 2024. PMID: 38493951
-
O-RADS MRI to classify adnexal tumors: from clinical problem to daily use.Insights Imaging. 2024 Jan 30;15(1):29. doi: 10.1186/s13244-023-01598-0. Insights Imaging. 2024. PMID: 38289563 Free PMC article.
-
Modified MR scoring system for assessment of sonographically indeterminate ovarian and adnexal masses in the absence of dynamic contrast-enhanced.Br J Radiol. 2024 Jan 23;97(1153):150-158. doi: 10.1093/bjr/tqad005. Br J Radiol. 2024. PMID: 38263830
-
Imaging of Acute Abdominopelvic Pain in Pregnancy and Puerperium-Part II: Non-Obstetric Complications.Diagnostics (Basel). 2023 Sep 11;13(18):2909. doi: 10.3390/diagnostics13182909. Diagnostics (Basel). 2023. PMID: 37761275 Free PMC article. Review.
-
Recurrent malignant ovarian adenocarcinoma with central nervous system metastasis successfully treated with paclitaxel, carboplatin, capecitabine, and gemcitabine.Proc (Bayl Univ Med Cent). 2022 Nov 8;36(2):234-236. doi: 10.1080/08998280.2022.2139538. eCollection 2023. Proc (Bayl Univ Med Cent). 2022. PMID: 36876271 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
